ORAMED PHARMACEUTICALS INC. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Oramed Pharmaceuticals made two loan participation investments in April–May 2026: (1) $2.5M participation in 83 Wythe Senior Investors' loan (April 15, 2026) for a real estate project with maturity extending to October 2029; (2) $3M participation in A&P Senior Investors' loan (May 13, 2026) for another project with maturity to May 2031. Both are subordinated to senior lenders and carry preferred returns of 9% and 8% annually respectively. Concurrently, Oramed Ltd. (Israel subsidiary) received a NIS 3.2M (~$890K) loan increase from a local lender, raising total debt to NIS 8.7M for project completion.
Why this rating
Combined $5.5M cash deployment is ~7% of $77.7M market cap—material absolute sum but minority of typical corporate size. Real estate loan participations are passive, subordinated investments with external lender control; low direct operational leverage on core pharma business. Israeli subsidiary loan is small and project-specific. No strategic tie to drug development or revenue.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.